Alpha-0261 Tablets for Moderate-to-Severe Ulcerative Colitis

The purpose of this protocol is to evaluate the safety and efficacy of Alpha-0261 in participants with moderately to severely active ulcerative colitis. The primary hypothesis is that Alpha-0261 is safe, and the secondary hypothesis is that Alpha-0261 is effective, as assessed by the proportion of participants achieving clinical remission per the complete modified Mayo score at Week 10.

NCT Number	NCT07744646
Lead Sponsor	The First Affiliated Hospital of Anhui Medical University Collaborators: AlphaMol Science Ltd. (Shanghai)
Conditions	Ulcerative Colitis (UC)
Enrollment	10 participants
Start Date	2026-08-03
Primary Completion	2027-01-09 (estimated)
Study Completion	2027-03-20 (estimated)
Updated on ClinicalTrials.gov	2026-08-04